rs10278336 — YKT6 GCK-Region Intronic Variant

The GCK-Region Variant: A Common Allele at the Glucose-Sensor Locus

Glucokinase (GCK) is the primary glucose sensor in pancreatic beta cells — the enzyme that tells the cell how much insulin to release in response to rising blood sugar. Variants in the GCK gene itself cause maturity-onset diabetes of the young type 2 (MODY2)¹¹ maturity-onset diabetes of the young type 2 (MODY2)
GCK-MODY is an autosomal dominant monogenic form of diabetes caused by heterozygous loss-of-function mutations in GCK. Individuals have a mild, stable fasting hyperglycemia throughout life, typically 5.5–8 mmol/L (99–144 mg/dL), that rarely progresses to diabetic complications and influence fasting glucose levels across the general population. rs10278336 sits in an intron of YKT6, a v-SNARE vesicle-trafficking gene immediately downstream of GCK on chromosome 7, within the same haplotype block. It is a GWAS-identified common risk allele for type 2 diabetes.

The Mechanism

rs10278336 is located at chr7:44,205,764 (GRCh38), approximately 16 kb downstream of the GCK gene body in an intron of YKT6. Its functional annotation is intronic — it does not change an amino acid or a splice site. The most likely mechanism is regulatory: variants in this region may sit in enhancer elements that influence GCK expression in pancreatic beta cells or hepatocytes, or may tag a broader GCK haplotype through linkage disequilibrium with functional variants upstream. The A allele at rs10278336 co-segregates with alleles at nearby GCK-region SNPs (including the well-studied rs4607517²² rs4607517
GCK intronic fasting-glucose GWAS variant; A allele at ~17% global frequency associates with elevated fasting glucose by reducing GCK expression) that collectively reduce GCK-mediated glucose sensing efficiency in beta cells. The net result is a small but detectable rightward shift in the fasting glucose set-point — the blood sugar level at which the pancreas judges it is time to release more insulin.

Unlike rare MODY2 mutations (which cause large, clinically obvious glucose elevations), common GWAS variants in this region each contribute only a few milligrams per deciliter to fasting glucose. Their cumulative effect, combined with other T2D risk variants, can meaningfully increase lifetime diabetes risk.

The Evidence

The primary evidence comes from a large-scale GWAS of type 2 diabetes³³ large-scale GWAS of type 2 diabetes
Morris AP et al. Large-scale association analysis provides insights into the genetic architecture and pathophysiology of type 2 diabetes. Nature Genetics 2012 (GWAS Catalog GCST005047), which identified rs10278336-A as a T2D risk allele with OR=1.07 (95% CI 1.04–1.10) at p=1×10⁻⁶. The effect size is modest and consistent with the polygenic architecture of common T2D — no single common variant contributes large risk, but the aggregate of dozens of variants is substantial.

A case-control study in 835 Chinese women with gestational diabetes⁴⁴ case-control study in 835 Chinese women with gestational diabetes
She L et al. Association of glucokinase gene and glucokinase regulatory protein gene polymorphisms with gestational diabetes mellitus. Gene 2022 (835 GDM cases, 870 controls) examined rs10278336 as part of a GCK-region panel and found no significant GDM association (P>0.05). However, the nearby GCK variant rs1799884 (-30G>A promoter) was significantly associated with GDM in this population, reinforcing that functional GCK-region variants do contribute to gestational glucose dysregulation. The null result for rs10278336 in GDM may reflect population-specific LD patterns in Han Chinese or insufficient statistical power.

The EPIC-InterAct study⁵⁵ EPIC-InterAct study
Langenberg C et al. Gene-lifestyle interaction and type 2 diabetes: the EPIC interact case-cohort study. PLoS Med 2014 (12,403 T2D cases from 9 European countries) found that the collective effect of T2D risk alleles — including GCK-region variants — was amplified in leaner individuals (p=7.49×10⁻⁹ for waist circumference interaction) and younger adults, but was not significantly modified by diet or physical activity at the population level. This suggests that for carriers of multiple T2D risk alleles, maintaining lean body composition may partially offset genetic risk.

Practical Actions

rs10278336 contributes a modest per-allele effect on T2D risk (OR~1.07). Its practical relevance is primarily in the context of cumulative polygenic risk: carriers of AA who also carry risk alleles at TCF7L2, KCNJ11, PPARG, and other major T2D loci face meaningfully elevated lifetime risk that justifies proactive monitoring. For AA homozygotes, fasting glucose tracking and attention to postprandial glucose patterns provide early warning before overt dysglycemia.

Dietary carbohydrate quality — specifically favoring low-glycemic-index sources — reduces the demand on GCK-mediated beta-cell glucose sensing: when carbohydrate absorption is slower, the acute glucose spike requiring precise incretin and GCK-mediated detection is lower. This is a mechanism-aligned (not generic) dietary strategy for this variant.

Interactions

rs10278336 acts within the GCK haplotype block. The neighboring rs4607517 (GCK intron) is a well-established fasting-glucose variant — both variants tag similar GCK regulatory architecture, and they are often in LD. A compound action covering both rs10278336-AA and rs4607517-AA (homozygous risk at both GCK-region loci) would be appropriate if both are confirmed in the same individual: the combined effect on fasting glucose would be additive.

The GCKR gene (glucokinase regulatory protein, chromosome 2) encodes a protein that sequesters GCK in the liver nucleus, buffering its activity. Variants in GCKR (rs780094, rs1260326) interact with GCK-region variants by modulating how much GCK activity is "released" to process incoming glucose. Carriers of GCK-region risk alleles who also carry GCKR high-expression variants face compounded impairment of hepatic glucose disposal.